Maven Securities’s Rigel Pharmaceuticals RIGL Stock Holding History

Maven Securities’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,591	Closed	-$112K	–	1239
2021 Q2	$112K	Buy	+2,591	New	+$97.8K	﹤0.01%	964

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Maven Securities's RIGL Position: Q3 2021 in Review

Maven Securities sold out of Rigel Pharmaceuticals (RIGL) in Q3 2021, closing a stake of 2,591 shares — an estimated $112K sold.

Maven Securities first reported a position in RIGL in Q2 2021 and held it in 1 quarter. The position peaked at $112K in Q2 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q3 2021.

Maven Securities reported no remaining Rigel Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Maven Securities sold 2,591 Rigel Pharmaceuticals shares in Q3 2021, an estimated $112K.
Maven Securities first reported a position in Rigel Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Maven Securities's Rigel Pharmaceuticals position peaked at $112K in Q2 2021.
163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.